Mayo Clinic licenses vaccine tech to TapImmune for all HER2/neu cancers

breast cancer
Breast cancer cells--Courtesy of National Cancer Institute

TapImmune, which focuses on infectious diseases and immuno-oncology, has chosen a tricky field, as cancer vaccines have seen limited success. But the biotech pushes on, licensing Mayo Clinic's HER2/neu vaccine technology to develop vaccines for any cancer where the HER2/neu gene is overexpressed.

Mayo Clinic initially licensed the technology to Jacksonville, FL’s TapImmune in 2012, for the development of a vaccine to treat HER2/neu breast cancer. That candidate has undergone Phase I trials, reporting positive safety and immune response data in June 2015. The company plans to bring it into Phase II trials at the beginning of 2017, it said in a statement Tuesday. While CEO Glynn Wilson said the candidate could be developed as a standalone vaccine or as part of a combination approach, he did not disclose any other cancers the company plans to target using Mayo Clinic’s platform.

The duo is also collaborating on a folate receptor alpha vaccine for patients with triple-negative breast cancer. These patients have no treatment options other than chemotherapy and surgery, but Wilson thinks TapImmune’s vaccine could work in 90% of women, compared to current vaccines that work in about 20% of women. TapImmune does not currently have any products on the market.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

TapImmune is working with AstraZeneca ($AZN) on a combination therapy for ovarian cancer, comprising the former’s anti-folate receptor vaccine and the latter’s anti-PD-L1 antibody, durvalumab. The treatment will enter Phase II trials this year.  Several high-profile companies, including GlaxoSmithKline ($GSK) and Merck KGaA, have developed cancer vaccines only to run into late-stage failures. But several companies hope combining their vaccines with checkpoint inhibitors like PD-L1 drugs will help realize their potential.

- here's the statement

Related Articles:
Bristol's Opdivo-Yervoy combo ups response rates in first-line lung cancer patients
Mayo Clinic secures $13.3M DOD grant to test TapImmune breast cancer vax
Cancer vaccines field to see sizable growth, report says
Immunotherapy combos could provide a new path forward for troubled cancer vaccine field


Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.